Please use this identifier to cite or link to this item: http://hdl.handle.net/1959.13/34597

OpenURL Link
Title
Pharmaceuticals, intellectual property and free trade: the case of the US-Australia free trade agreement
Author/Creator
Drahos, Peter;  Lokuge, Buddhima;  Faunce, Tom;  Goddard, Martyn;  Henry, David
Institution
The University of Newcastle. Faculty of Health, School of Medicine and Public Health
Description
Australia did poorly in several key areas of the recently completed free trade agreement with the US. It failed to insulate the Pharmaceutical Benefits Scheme (PBS) from significant change, and conceded to increased intellectual property standards. The PBS, as a system of effective bargaining with multinational pharmaceutical firms, has been deeply compromised and higher drug prices can be expected over time. The intellectual property chapter strengthens the position of patent owners and undermines the evolution of a competitive generics industry. These developments are part of a broader and internationally coordinated strategy being pursued by pharmaceutical multinationals to globalize and strengthen patent rights and monopoly profits.
Relation
Prometheus Vol. 22, Issue 3, p. 243-257
Publisher Link
http://dx.doi.org/10.1080/0810902042000255705
Date
2004
Publisher
Routledge
Keyword(s)
free trade agreements;  intellectual property;  pharmaceutical benefits scheme;  bargaining
Resource Type
journal article
Identifier
http://hdl.handle.net/1959.13/34597
Identifier
ISSN:0810-9028
Reviewed
Reviewed
14 Visitors 17 Hits 0 Downloads
Save/E-mail Citation
Citation Format
E-mail Address
Subject
"Prometheus"
 
OR